Marina Udier
Directeur/Membre du Conseil chez CELYAD ONCOLOGY SA
Provenance du réseau au premier degré de Marina Udier
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 45 | |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.
13
| Holding Company | Pharmaceuticals: Major | 13 |
Nouscom Srl
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Marina Udier via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| Université Catholique de Louvain | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree Undergraduate Degree | |
| Université Libre de Bruxelles | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal | |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder Corporate Officer/Principal Director/Board Member | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| MedPole SA/NV | Chief Executive Officer Chief Operating Officer Director of Finance/CFO | ||
| The American University of Rome | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
| VOLCANO CORPORATION | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| NANEXA AB | Medical Specialties | Chairman Director/Board Member | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Chief Executive Officer General Counsel | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Chief Executive Officer Director/Board Member | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Antwerp | College/University | Doctorate Degree Doctorate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| Wayne State University (Michigan) | College/University | Undergraduate Degree Undergraduate Degree | |
| Università degli Studi di Napoli Federico II | College/University | Undergraduate Degree Doctorate Degree | |
Reithera Srl
 Reithera Srl Real Estate Investment TrustsFinance Reithera Srl is a biotech company based in Rome, Italy. The Italian company specializes in viral vector production and is a leading contract development and manufacturing organization. The company has a new 1,500 sq.m. facility that has been granted operational authorization from AIFA, the Italian Medicines Agency, which will allow them to consolidate their competitive position. Reithera's international team has contributed to several research projects aimed at unlocking the potential of innovative prophylactic and therapeutic programs. The company aims to unlock the potential of vector gene-delivery platforms by exploiting adenovirus, MVA, AAV, helper-dependent vectors, and rhabdovirus. The CEO of the company is Antonella Folgori. | Real Estate Investment Trusts | Founder Founder | |
| ICHEC | College/University | Graduate Degree Graduate Degree | |
| RADIUS HEALTH, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
Hendigo NV
 Hendigo NV Financial ConglomeratesFinance Hendigo NV is an investment holding Belgian company founded in 2013. The private company operates as an investment holding company. | Financial Conglomerates | Director/Board Member Director/Board Member | |
| Université de Namur ASBL | College/University | Graduate Degree Graduate Degree | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Biological Manufacturing Services SA | Director/Board Member Director of Finance/CFO | ||
| University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
Bryan, Garnier & Co Ltd.
 Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Investment Banks/Brokers | Corporate Officer/Principal | |
Ncardia SA
 Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
| Medical University of Silesia | College/University | Doctorate Degree | |
Participatiemaatschappij Vlaanderen NV
 Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor | |
| BIOTALYS NV | Chemicals: Agricultural | Director/Board Member | |
20Med Therapeutics BV
 20Med Therapeutics BV BiotechnologyHealth Technology 20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands. | Biotechnology | Director/Board Member | |
| DMS IMAGING | Biotechnology | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Thémis SA | Director/Board Member | ||
European Vaccine Initiative
 European Vaccine Initiative BiotechnologyHealth Technology The European Vaccine Initiative manufactures vaccines. The private company is based in London, UK. | Biotechnology | Corporate Officer/Principal | |
St. Christopher's Hospital for Children LLC
 St. Christopher's Hospital for Children LLC Medical/Nursing ServicesHealth Services St. Christopher's Hospital for Children LLC provides pediatric, children care services, family advisory council, nurturing and culturally diverse environment. Its services include anesthesiology, audiology, cardiology, and center for the urban child, child life program, child protection program, critical care, dental medicine, developmental pediatrics, ear nose throat, emergency, hepatology nutrition and genetics. The company was founded by William H. Bennett on November 30, 1875 and is headquartered in Philadelphia, PA. | Medical/Nursing Services | Corporate Officer/Principal | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member | |
PDC Line Pharma SASU
 PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | Pharmaceuticals: Major | Director/Board Member | |
Henogen SA
 Henogen SA Pharmaceuticals: MajorHealth Technology Henogen SA develops and manufactures biopharmaceuticals. The company was founded on November 19, 1999 and is headquartered in Charleroi, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
| University of Pittsburgh | College/University | Corporate Officer/Principal |
Statistiques
Internationale
| Belgique | 19 |
| Etats-Unis | 14 |
| France | 6 |
| Suisse | 4 |
| Italie | 4 |
Sectorielle
| Health Technology | 24 |
| Consumer Services | 14 |
| Finance | 6 |
| Commercial Services | 3 |
| Health Services | 3 |
Opérationnelle
| Director/Board Member | 244 |
| Corporate Officer/Principal | 99 |
| Chairman | 60 |
| Independent Dir/Board Member | 48 |
| Chief Executive Officer | 41 |
Relations les plus connectées
| Insiders | |
|---|---|
| Göran Albert Ando | 44 |
| Scott Rocklage | 32 |
| Jean-Paul Prieels | 32 |
| Guido Magni | 23 |
| Hanspeter Spek | 23 |
| Jean-Marc Heynderickx | 22 |
| Joachim Rothe | 22 |
| Serge Goblet | 20 |
| Michel Lussier | 20 |
| Genghis Lloyd-Harris | 19 |
| Debasish Francois Roychowdhury | 18 |
| Hilde Windels | 18 |
| Vincent Brichard | 15 |
| Chris de Jonghe | 15 |
| John McDonald | 11 |
- Bourse
- Insiders
- Marina Udier
- Connexions Sociétés
